Roche’s Q2 Results Reaffirm Our Bullish Stance
Roche (NASDAQ: RHHBY) reported its Q2 results on 21 July,2016. The company continued to show strong growth in its oncology division. Even the diagnostic division was not behind. Considering the strong growth, we continue to remain bullish on Roche shares.
Key Takeaways From Q2 Earnings
1) Oncology Continues To Show Strong Growth
2) Diagnostics Division Saw Growth Boost
3) International Expansion Seems To Be The Major Reason
4) Overall We Continue To Maintain Bullish Stance
Sources:
[1] Roche Holding’s (RHHBY) CEO Severin Schwan on Q2 2016 Results – Earnings Call Transcript, Seeking Alpha, July 21,2016
[2] Roche Earnings Q2 Results, Roche, July 21,2016
Have more questions about Roche? See the links below.
- Roche’s Stock May Have Been Down, But The Company’s Business Has Strong Outlook
- What Drove 15% Growth in Roche’s Earnings Between 2011-2014 Even Though Other Big Pharma Companies Suffered A Decline?
- Why Is Market Assigning Low Earnings Multiple To Roche Despite Its Biotech Focus?
- Can Roche Grow Its Earnings By 15% In The Next 3 Years?
- With Biosimilars Getting Approval In Europe, Does Roche’s 2016 EPS Face A Meaningful Risk?
- How Can Roche Get 25% Boost In Revenues In 5 Years?
- Can Emerging Biosimilar Competition Cause > 10% Downside To Roche’s Valuation?
- Here Is Why We Are Bullish On Roche
- Three Things To Watch Out For Roche This Year
Notes:
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)